Breast Cancer Core Needle Biopsy (CNB) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Breast Cancer Core Needle Biopsy (CNB) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

The Global Breast Cancer Core Needle Biopsy Market was valued at USD 776.5 million in 2023 and is projected to expand at a CAGR of 7.8% from 2024 to 2032, driven by the rising incidence of breast cancer, leading to heightened demand for early diagnosis.

The World Health Organization (WHO) reported that around 2.3 million women were diagnosed with breast cancer worldwide in 2022. This trend has spurred the adoption of various biopsy techniques, notably Core Needle Biopsy (CNB). Growing awareness among women about early breast cancer detection has increased demand for cancer screening programs, intensifying the need for minimally invasive diagnostic procedures like CNB.

The demand for cancer screening and diagnostic services has significantly propelled the market for breast cancer core needle biopsies. Innovations in imaging technologies and breast biopsy devices are enhancing the accuracy and safety of CNB, boosting its adoption in both developed and emerging markets.

The overall breast cancer core needle biopsy industry is classified based on image-guided technology, end-user, and region.

The ultrasound-guided segment dominates the market and is projected to grow at a CAGR of 7.6% during the forecast period. Its prominence stems from its accuracy and non-invasive approach. Utilizing real-time ultrasound imaging, this technique precisely targets suspicious breast tissue, ensuring biopsy samples are taken from the exact area of concern. Benefits include reduced procedure time, minimal patient discomfort, and immediate biopsy site visualization. Its cost-effectiveness and seamless integration into clinical practices further cement its leading position in the breast cancer core needle biopsy (CNB) market.

In 2023, hospitals commanded the largest market share at 48.4%. Their dominance is rooted in extensive diagnostic capabilities and state-of-the-art facilities. Offering a suite of imaging technologies, from ultrasound to mammography, alongside biopsy procedures, hospitals ensure heightened accuracy and patient care. Their ability to manage intricate cases, backed by specialized medical teams and comprehensive follow-up care, enriches the diagnostic journey. High patient volumes and robust infrastructure drive the widespread adoption of these diagnostic procedures in hospitals.

In 2023, the U.S. breast cancer CNB market was valued at USD 320.3 million, due to a high breast cancer incidence and a growing demand for effective diagnostic solutions. The American Cancer Society notes that roughly 1 in 8 women, or about 13% of the U.S. female population, will face a breast cancer diagnosis in their lifetime. Projections for 2024 suggest breast cancer will represent nearly 30% of all new cancer diagnoses among females. This statistic highlights the urgent need for efficient diagnostic tools and procedures. Ongoing technological advancements in biopsy devices and supportive reimbursement policies bolster the market's growth trajectory.